1. Home
  2. CGEM vs VSTM Comparison

CGEM vs VSTM Comparison

Compare CGEM & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.19

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$6.85

Market Cap

723.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
VSTM
Founded
2016
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
671.7M
723.8M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
CGEM
VSTM
Price
$10.19
$6.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
9
Target Price
$28.00
$13.38
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
02-26-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,379,000.00
Revenue This Year
N/A
$208.54
Revenue Next Year
N/A
$251.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.79
52 Week Low
$5.68
$4.01
52 Week High
$13.33
$11.25

Technical Indicators

Market Signals
Indicator
CGEM
VSTM
Relative Strength Index (RSI) 49.47 29.57
Support Level $9.41 $6.68
Resistance Level $10.70 $8.14
Average True Range (ATR) 0.61 0.49
MACD -0.12 -0.15
Stochastic Oscillator 40.66 6.52

Price Performance

Historical Comparison
CGEM
VSTM

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Share on Social Networks: